MiNK Therapeutics Inc Dossier
Qualitative Analysis
Business overview
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company pioneering the discovery, development, and manufacturing of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a unique class of immune cells that combine the rapid, potent cytotoxicity of natural killer (NK) cells with the durable memory response of T cells, effectively bridging the innate and adaptive immune systems. The company's proprietary platform is designed to deliver off-the-shelf therapies that can be administered without the need for patient-specific HLA matching or lymphodepletion. MiNK's lead product candidate is agenT-797, a native, non-engineered allogeneic iNKT cell therapy currently in clinical development for solid tumors (such as gastric cancer) and viral acute respiratory distress syndrome (ARDS). Additionally, the company is advancing next-generation engineered CAR-iNKT programs, including MiNK-215 (targeting FAP) and MiNK-413 (targeting BCMA).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead candidate agenT-797 into a randomized Phase 2 trial for severe acute lung injury and acute respiratory distress syndrome (ARDS) to address a large market opportunity of 200,000–300,000 patients annually in the US and Europe.
Expected impact: Establish clinical proof-of-concept for allogeneic iNKT cells in severe inflammatory pulmonary conditions.
Securing external, non-dilutive funding sources, including federal grants, philanthropic awards, and consortium partnerships, to advance pipeline programs while preserving cash runway.
Expected impact: Extends cash runway through 2026 and reduces the capital burden of early-stage clinical trials.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Enables the development of a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, leveraging MiNK's proprietary iNKT platform in high-need oncology settings.
Terms: MiNK receives approximately $1.1 million in non-dilutive, aggregate funding to support IND-enabling development, with potential double-digit downstream commercial revenue participation.